A
42.12
-1.55 (-3.55%)
| Previous Close | 43.67 |
| Open | 43.50 |
| Volume | 947,727 |
| Avg. Volume (3M) | 1,285,834 |
| Market Cap | 3,353,598,464 |
| Price / Book | 4.47 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.75 |
| Total Debt/Equity (MRQ) | 4.81% |
| Current Ratio (MRQ) | 19.38 |
| Operating Cash Flow (TTM) | -230.11 M |
| Levered Free Cash Flow (TTM) | -148.48 M |
| Return on Assets (TTM) | -25.37% |
| Return on Equity (TTM) | -39.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Akero Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 3.0 |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.39% |
| % Held by Institutions | 93.46% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 109.00 (UBS, 158.78%) | Buy |
| Median | 77.50 (84.00%) | |
| Low | 63.00 (B of A Securities, 49.57%) | Buy |
| Average | 82.67 (96.27%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 51.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Mar 2025 | 75.00 (78.06%) | Buy | 45.54 |
| 27 Jan 2025 | 72.00 (70.94%) | Buy | 51.71 | |
| UBS | 31 Jan 2025 | 109.00 (158.78%) | Buy | 54.08 |
| B of A Securities | 30 Jan 2025 | 63.00 (49.57%) | Buy | 55.36 |
| Canaccord Genuity | 28 Jan 2025 | 73.00 (73.31%) | Buy | 51.47 |
| Citigroup | 28 Jan 2025 | 80.00 (89.93%) | Buy | 51.47 |
| Morgan Stanley | 28 Jan 2025 | 96.00 (127.92%) | Buy | 51.47 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LAMY PATRICK | - | 45.54 | -1,000 | -45,540 |
| YOUNG JONATHAN | - | 44.53 | -50,000 | -2,226,500 |
| Aggregate Net Quantity | -51,000 | |||
| Aggregate Net Value ($) | -2,272,040 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 45.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| YOUNG JONATHAN | Officer | 04 Mar 2025 | Automatic sell (-) | 50,000 | 44.53 | 2,226,500 |
| LAMY PATRICK | Officer | 03 Mar 2025 | Automatic sell (-) | 1,000 | 45.54 | 45,540 |
| LAMY PATRICK | Officer | 03 Mar 2025 | Option execute | 1,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |